We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
mpMRI-US Fusion-Guided Targeted Cryotherapy in Patients with Primary Localized Prostate Cancer: A Prospective Analysis of Oncological and Functional Outcomes.
- Authors
Fernández-Pascual, Esaú; Manfredi, Celeste; Martín, Cristina; Martínez-Ballesteros, Claudio; Balmori, Carlos; Lledó-García, Enrique; Quintana, Luis Miguel; Curvo, Raphael; Carballido-Rodríguez, Joaquín; Bianco Jr., Fernando J.; Martínez-Salamanca, Juan Ignacio
- Abstract
Simple Summary: Targeted cryotherapy is an emerging treatment for prostate cancer (PCa). mpMRI is a powerful tool for image fusion techniques that deliver incremental precision in diagnostic and treatment of PCa. Fusion targeted cryotherapy (FTC) arises from the simultaneous application of both these procedures. Recurrence is a concern after any type of PCa treatment, especially after targeted treatments. In this article we investigate the recurrence rate after FTC and the role of Prostate-Specific Antigen (PSA) as a predictor of recurrences. Our research provides new evidence on the feasibility of FCT by providing new insights on patient management. Targeted therapy (TT) for prostate cancer (PCa) aims to ablate the malignant lesion with an adequate margin of safety in order to obtain similar oncological outcomes, but with less toxicity than radical treatments. The main aim of this study was to evaluate the recurrence rate (RR) in patients with primary localized PCa undergoing mpMRI/US fusion targeted cryotherapy (FTC). A secondary objective was to evaluate prostate-specific antigen (PSA) as a predictor of recurrences. We designed a prospective single-center single-cohort study. Patients with primary localized PCa, mono or multifocal lesions, PSA ≤ 15 ng/mL, and a Gleason score (GS) ≤ 4 + 3 undergoing FTC were enrolled. RR was chosen as the primary outcome. Recurrence was defined as the presence of clinically significant prostate cancer in the treated areas. PSA values measured at different times were tested as predictors of recurrence. Continuous variables were assessed with the Bayesian t-test and categorical assessments with the chix-squared test. Univariate and logistic regression assessment were used for predictions. A total of 75 cases were included in the study. Ten subjects developed a recurrence (RR: 15.2%), while fifty-six (84.8%) patients showed a recurrence-free status. A %PSA drop of 31.5% during the first 12 months after treatment predicted a recurrence with a sensitivity of 53.8% and a specificity of 79.2%. A PSA drop of 55.3% 12 months after treatment predicted a recurrence with a sensitivity of 91.7% and a specificity of 51.9%. FTC for primary localized PCa seems to be associated with a low but not negligible percentage of recurrences. Serum PSA levels may have a role indicating RR.
- Subjects
STATISTICS; COLD therapy; FUNCTIONAL status; MAGNETIC resonance imaging; CANCER relapse; T-test (Statistics); TREATMENT effectiveness; DESCRIPTIVE statistics; PROSTATE-specific antigen; LOGISTIC regression analysis; SENSITIVITY &; specificity (Statistics); PROSTATE tumors; LONGITUDINAL method; TUMOR grading
- Publication
Cancers, 2022, Vol 14, Issue 12, p2988
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers14122988